Kian Sadeghi

Kian Sadeghi runs Nucleus Genomics out of New York, where the pitch is deceptively simple: read your entire genome once, and keep the answers for life. Spit in a tube, and Nucleus returns a clinical-grade whole-genome sequence the company says can stand in for tens of thousands of separate genetic tests. The product he keeps describing - "your genome in your pocket, on your smartphone" - is the kind of line founders use when they would rather you remembered the destination than the lab work.

He is in his mid-twenties and has been arguing about DNA in public for years now. Nucleus has raised roughly $32 million, including a $14 million Series A in January 2025, from a roster that reads like a Silicon Valley group chat: Peter Thiel, Alexis Ohanian's Seven Seven Six, Balaji Srinivasan, Founders Fund, Asylum Ventures and Samsung Next among them. By 2025 the company had grown to around 41 people. None of that is the interesting part. The interesting part is the year he spent in a cave with a flashlight.

The 18 notebooks

Before Nucleus, before the Thiel Fellowship, there was a Brooklyn apartment and a stack of notebooks. After watching the cost of sequencing a human genome collapse from roughly $1 billion to about $1,000, Sadeghi left the University of Pennsylvania - where he had been studying computational biology - and gave himself a year to learn genetics from the ground up. He filled 18 notebooks. He told his parents he was working in a lab. He was not.

Across the margins of those notebooks he kept writing the same two words: Just keep going. He has described the stretch as "being in a cave with a little flashlight," the sort of work that requires faith that something is on the other side of it. It is a strange way to start a venture-backed company - no co-founder spreadsheet, no incubator, just a 20-year-old and a self-imposed curriculum he hid from the people who raised him.

Before the cave: yeast, bacteria, and a DIY lab

The flashlight year did not come from nowhere. As a teenager, Sadeghi had already talked his way into one of the first DIY community genetics labs in the country, the kind of place where amateurs engineer yeast and bacteria for the joy of watching biology do what it is told. That is where the instinct formed: that genetics was not a priesthood, that you could get your hands on it, that the tools were closer than they looked. Penn and its computational biology program came next, and then - just as quickly - went.

The cousin

Ask him why any of this matters and the answer goes back to a death in the family. A young cousin died suddenly, a loss later attributed to a suspected heart-rhythm disorder. When Sadeghi asked his father how something like that happens, the answer was two words that would not leave him alone: bad genetics. He has said it was the first time he intuitively grasped the idea of "generational health" - the notion that what runs in a family is not a verdict but a problem, and problems can be worked on. Nucleus is, in a real sense, an argument with that two-word explanation.

"I realized that an accessible health platform that uses genomics and lifestyle data to analyze disease risks could have made a life-changing impact on my family," he has said. "That's what we want to build for everyone." The product roadmap follows the obsession. Nucleus's claim is that whole-genome sequencing "supersedes nearly all the others, from single-gene tests for hereditary cancers to small panels and carrier screenings" - that one deep read can replace the scavenger hunt of one-off tests families currently navigate.

The argument he refuses to soften

Here is where Sadeghi diverges from the playbook. Most young biotech founders learn to speak in careful, hedged sentences. He leans the other way. Nucleus has openly marketed "genetic optimization" - embryo screening that touches not just disease risk but traits - and the response has been loud, skeptical, and at times furious. Geneticists have disputed the strength of the predictions. Critics have reached for heavy words. Sadeghi's instinct is not to retreat but to publish.

"Once you start trying to hide science, people overextrapolate and make up stories that simply aren't true," he has said - a tidy summary of his media strategy, which is essentially to keep showing up. CBS, podcasts, fireside chats at Johns Hopkins, long profiles in the tech press: he treats scrutiny as distribution. He has even reframed the core obstacle to consumer genomics not as a scientific limitation but as a marketing one, noting that preconception screening is already recommended by professional bodies and simply under-adopted. Whatever you make of the conclusion, it is a genuinely contrarian read on his own industry.

What the company actually ships

Underneath the debate is a product line that keeps widening. The core is a consumer whole-genome sequence - the deep read Sadeghi argues can replace the patchwork of single-gene tests, small panels and carrier screens that families currently pay for one at a time. On top of that, 2025 brought a pair of moves aimed squarely at how people plan families: a DNA matching feature for prospective parents and an IVF+ fertility program run with partner clinics. Early that year Nucleus also acquired Cambrean, an AI health-data platform, folding more software into a company that began as one person's reading list.

The framing he returns to is that the bottleneck is adoption, not capability. Preconception genetic screening is already recommended by professional bodies, he notes, and still most couples never do it. He calls that a marketing problem - a phrase that lands strangely in an industry trained to talk about clinical validation first. But it is consistent with everything else about him: the DIY-lab teenager who thought genetics should be in more hands, the dropout who bet a year of his life that the tools were ready, the CEO who would rather over-explain on camera than let the technology stay mysterious. He is selling access as much as science.

That conviction is also why the investor list matters beyond the dollar figure. Thiel, Ohanian, Srinivasan and Founders Fund are not subtle bets; they are the part of Silicon Valley most comfortable with the idea that biology is software waiting to be edited. Sadeghi fits that worldview and pushes it into the most sensitive room in medicine - the one where people decide whether and how to have children. Plenty of founders would rather not be the face of that conversation. He volunteered.

What makes him worth watching is the gap between the two halves of the story. There is the founder who will debate trait prediction on camera, and there is the kid who wrote "just keep going" in the margins because nobody was watching yet. The first one gets the headlines. The second one is the reason there is a company at all. When a patient's result comes back flagging a serious inherited risk, Sadeghi has said, he thinks: maybe we just saved that person's life. It is the same impulse that started in the DIY lab and survived the cave - the belief that the answer to "bad genetics" is not resignation. It is information, handed to the people it belongs to.